← All organizations

Par Pharmaceuticals

For profitContributed to NME

Also known as: PAR FORM | PAR FORMULATIONS PRIVATE LTD | PAR PHARM | Par Pharmaceutical Companies, Inc. | Par Pharmaceutical, Inc. | PAR PHARM INC | PAR STERILE PRODUCTS

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Jun 30, 2016

Acquired by Endo Pharmaceuticals → Mallinckrodt (2013) on May 18, 2015

Timeline

1970s

Jul 12, 1974
trimethobenzamide— NDA Organization
Jun 1, 1978
Par Pharmaceuticals— Founded

2010s

Aug 24, 2011
Anchen Pharmaceuticals, Inc— Acquired
Dec 7, 2012
epinephrine— NDA Secondary Org
Jan 21, 2014
JHP Pharmaceuticals LLC— Acquired
Jan 1, 2015
Ethics Bio Lab— Acquired
May 18, 2015
Endo Pharmaceuticals— Acquired By
Apr 15, 2016
sodium phenylbutyrate— Marketing Organization

2020s

Mar 1, 2025
Mallinckrodt (2013)— Now

Drugs by trial phase (22 distinct, 43 trials)

Phase 3 (5 own, 2 via acquisition)

Phase 2 (1 own, 1 via acquisition)

Phase 1 (13 own, 0 via acquisition)

Subsidiaries (3 direct, 3 total across the full acquisition tree)

Recent trials (43)

NCT03297502Lead sponsorPhase 3Jun 30, 2016
NCT01994642Study directorPhase 3Nov 1, 2013
NCT01994642Lead sponsorPhase 3Nov 1, 2013
NCT01910155Lead sponsorPhase 3Jul 1, 2013
NCT01910155Study directorPhase 3Jul 1, 2013
NCT01217190Lead sponsorPhase 3Sep 1, 2008
NCT01220167Lead sponsorPhase 3Aug 1, 2008
NCT00637728Study chairPhase 3Jun 1, 2006
NCT00637806Study chairPhase 3Jun 1, 2006
NCT00637728Lead sponsorPhase 3Jun 1, 2006
NCT00637806Lead sponsorPhase 3Jun 1, 2006
NCT00637403Lead sponsorPhase 1May 1, 2006
NCT00637403Study directorPhase 1May 1, 2006
NCT01380457Lead sponsorPhase 1Jan 1, 2006
NCT00652600Lead sponsorPhase 1Sep 1, 2005

Details

Founded: Malvern, PA, US Jun 1, 1978
First NDA: May 15, 1979
Last known activity: Jun 30, 2016

Designations held

Orphan drug
Priority review